Abstract |
T-cell acute lymphoblastic leukemia (ALL) accounts for 15% of ALL cases in children and has been associated with a worse prognosis. Cytogenetic studies show an abnormal karyotype in 50-60% of the T-cell ALL patients; ABL1 fusions are present in approximately 8% of the cases. Dasatinib, a second-generation tyrosine kinase inhibitor, directly targets the BCR-ABL gene. We describe a pediatric case of T-cell ALL with amplification of the ABL1 gene in which remission was achieved only after the addition of dasatinib to conventional chemotherapy.
|
Authors | Ofelia Crombet, Kelly Lastrapes, Arthur Zieske, Jaime Morales-Arias |
Journal | Pediatric blood & cancer
(Pediatr Blood Cancer)
Vol. 59
Issue 2
Pg. 333-4
(Aug 2012)
ISSN: 1545-5017 [Electronic] United States |
PMID | 22689211
(Publication Type: Case Reports, Journal Article)
|
Copyright | Copyright © 2011 Wiley Periodicals, Inc. |
Chemical References |
- Protein Kinase Inhibitors
- Pyrimidines
- Thiazoles
- Proto-Oncogene Proteins c-abl
- Dasatinib
|
Topics |
- Child
- Dasatinib
- Female
- Gene Amplification
- Humans
- Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
(drug therapy, genetics, pathology)
- Protein Kinase Inhibitors
(therapeutic use)
- Proto-Oncogene Proteins c-abl
(genetics)
- Pyrimidines
(therapeutic use)
- Remission Induction
- Thiazoles
(therapeutic use)
|